About
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. It works independently of insulin by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This mechanism results in a reduction in blood glucose levels, a modest reduction in body weight, and a decrease in blood pressure. Beyond its glycemic benefits, dapagliflozin has demonstrated significant cardiovascular and renal protective effects, making it a valuable option for patients with type 2 diabetes who also have established cardiovascular disease, heart failure, or chronic kidney disease. It is often used as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents.
Uses
- Treatment of type 2 diabetes mellitus.
- Reduction of risk of cardiovascular death and hospitalization for heart failure.
- Reduction of risk of kidney disease progression.
- Adjunct to diet and exercise.
Directions For Use
Take dapagliflozin orally once daily in the morning, with or without food, as directed by your doctor.
Benefits
- Lowers blood glucose levels effectively.
- Reduces HbA1c.
- Promotes modest weight loss.
- Lowers blood pressure.
- Provides cardiovascular benefits (reduced heart failure hospitalization).
- Offers renal protective effects.
Side Effects
- Genital mycotic infections (e.g., yeast infections)
- Urinary tract infections
- Increased urination
- Thirst
- Dizziness
- Hypotension (especially in dehydrated patients)
- Ketoacidosis (rare, but serious)
- Kidney problems (rare)
- Back pain
- Nausea
- Constipation
- Flu-like symptoms
Safety Measures
- Alcohol - Excessive alcohol intake may increase the risk of dehydration and ketoacidosis. Use with caution.
- Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on kidney development.
- Breastfeeding - Not recommended during breastfeeding as it is unknown if dapagliflozin is excreted in human milk.
- Liver - No dose adjustment is generally needed for mild to moderate liver impairment. Use with caution in severe impairment.
- Kidney - Not recommended for patients with severe kidney impairment (eGFR <25 mL/min/1.73m²) for glycemic control.
- Lung - Generally safe for use in patients with lung conditions; no specific contraindications related to pulmonary function.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!